A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

por Aaron S. Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama N. Waqar, Andrew E. Hendifar, Lowell B. Anthony, Matthew H. Taylor, Alan H. Bryce, Scott T. Tagawa, Karl Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, Rahul Aggarwal
Publicado 2021

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival

por Hui Zheng, Eirini Pectasides, Mohamed Uduman, Charles S Fuchs, James M Cleary, Adam J Bass, Jérémy Augustin, Leonie K de Klerk, Anuj K Patel, Sarah Derks, Nihal Raman, Fahire G Akarca, Nadine J McCleary, Douglas A Rubinson, Jeffrey W Clark, Bridget Fitzpatrick, Lauren K Brais, Megan E Cavanaugh, Amanda J Rode, Melissa G Jean, Patrick H Lizotte, Matthew J Nazzaro, Peter C Enzinger
Publicado 2021